Egg proteins and peptides in human health-chemistry, bioactivity and production

Current Pharmaceutical Design

Volumn 13, Issue 9, 2007, Pages 875-884

  Mine, Yoshinori ^a  

^a UNIVERSITY OF GUELPH   (Canada)

Author keywords

Avian eggs; Bio active proteins and peptides; Chronic diseases; Eegg white; Functional foods; Human health; Nutraceuticals; Yolk

Indexed keywords

ANTIBIOTIC AGENT; AVIDIN; BETA LACTAMASE; CEREBROSIDE; CHOLESTEROL; CYSTATIN; DIPEPTIDYL CARBOXYPEPTIDASE; EGG PROTEIN; GAMMA INTERFERON; GLYCOLIPID; IMMUNOGLOBULIN Y; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; LYSOZYME; NITRIC OXIDE; OTAP 92; OVALBUMIN; OVOKININ; OVOMUCOID; OVOTRANSFERRIN; PEPTIDE DERIVATIVE; PHOSVITIN; PROTEIN DERIVATIVE; SYN 2190; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIHYPERTENSIVE ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIVIRAL ACTIVITY; BACILLUS CEREUS; CANCER INHIBITION; CHRONIC SINUSITIS; CYTOKINE RELEASE; DENTAL CARIES; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG POTENTIATION; EGG; EGG SHELL; EGG YOLK; ENZYME INHIBITION; ESCHERICHIA COLI; FOOD COMPOSITION; HUMAN; HYPERTENSION; IMMUNOMODULATION; INFLUENZA VIRUS; NONHUMAN; PANCREATITIS; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVIEW; ROTAVIRUS; SNAKEBITE; SOLID TUMOR; SPIDER BITE; ULCERATIVE COLITIS; VIRAL SKIN DISEASE; VISCERAL LEISHMANIASIS;

ANIMALS; BIRDS; EGG PROTEINS; EGG SHELL; EGG WHITE; EGG YOLK; HEALTH; HUMANS; HYDROLYSIS; PEPTIDES; TECHNOLOGY, PHARMACEUTICAL;

EID: 34247228937     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207780414278     Document Type: Review

References (169)

1. Burley RW, Vadehra DV. In: Burley RW, Vadehra DV Eds, The avian egg, chemistry and biology. New York: John Wiley & Sons, Inc 1989; 1-16.
2. Li-Chan ECY, Powrie WD, Nakai S, Stadelman WJ, Cotterill OJ Eds, Egg Science and Technology, 4th ed. New York: The Haworth Press, Inc 1995; 105-75.
3. Burley RW, Cook WH. Isolation and composition of avian egg yolk granules and their constituents α- and β-lipovitellines. Can J Biochem Physiol 1961; 39: 1295-307.
4. Itoh T, Miyazaki J, Sugawara H, Adachi S. Studies on the characterization of ovomucin and chalaza of the hen's egg. J Food Sci 1987; 52: 1518-21.
5. Kato A, Oda S, Yamanaka Y, Matsudomi N, Kobayashi K. Functional and structural properties of ovomucin. Agric Biol Chem 1985; 49: 3501-4.
6. Tsuge Y, Shimoyamada M, Watanabe K. Differences in hemagglutination inhibition activity against bovine rotavirus and hen newcastle disease virus based on the subunits in hen egg white ovomucin. Biosci Biotech Biochem 1996; 60: 1505-6.
7. Tsuge Y, Shimoyamada M, Watanabe K. Binding of egg white proteins to viruses. Biosci Biotech Biochem 1996; 60: 1503-4.
8. Tsuge Y, Shimoyamada M, Watanabe K. Bindings of ovomucin to newcastle disease virus and anti-ovomucin antibodies and its heat stability based on binding abilities. J Agric Food Chem 1997; 45: 4629-34.
9. Watanabe K, Tsuge Y, Shimoyamada M. Binding activities of pronase-treated fragments from egg white ovomucin with anti-ovomucin antibodies and newcastle disease virus. J Agric Food Chem 1998; 46: 4501-6.
10. Watanabe K, Tsuge Y, Shimoyamada M, Ogama N, Ebina T. Antitumor effects of pronase-treated fragments, glycopeptides, from ovomucin in hen egg white in a double grafted tumor system. J Agric Food Chem 1998; 46: 3033-8.
11. Oguro T, Ohaki Y, Asano G, Ebina T, Watanabe K. Ultrastructural and immunohistochemical characterization on the effect of ovomucin in tumor angiogenesis. Jpn J Clin Electron Microsc 2001; 33: 89-99.
12. Tanizaki H, Tanaka H, Iwata H, Kato A. Activation of macrophages by sulfated glycopeptides in ovomucin, yolk membrane, and chalazae in chicken eggs. Biosci Biotech Biochem 1997; 61: 1883-9.
13. Nagaoka S, Masaoka M, Zhang Q, Hasegawa M, Watanabe K. Egg ovomucin attenuates hypercholesterolemia in rats and inhibits cholesterol absorption in Caco-2 cells. Lipids 2002; 37: 267-72.
14. Ibrahim HR. Ovotransferrin. In: Naidu AS Ed, Natural food antimicrobial systems. New York: CRC Press, Inc 2000; 211-6.
15. Abdallah FB, Hage Chahine J-M EI. Transferrins, the mechanism of iron release by ovotransferrin. Eur J Biochem 1999; 263: 912-20.
16. Valenti P, Antonini G, Von Hunolstein C, Visca P, Orsi N, Antonini E. Studies of the antimicrobial activity of ovotransferrin. Int J Tissue React 1983; 5: 97-105.
17. Baron F, Fauvel S, Gautier M, Sim JS, Nakai S, Guenter W Eds. Egg Nutrition and Biotechnology. Oxon, UK: CAB International 2000; 417-30.
18. Valenti P, Antonini G, Fanelli MR, Orsi N, Antonini E. Antibacterial activity of matrix-bound ovotransferrin. Antimicrob Agents Chemother 1982; 21: 840-1.
19. Valenti P, Visca P, Antonini G, Orsi N. Antifungal activity of ovotransferrin towards genus Candida. Mycopathologia 1985; 89: 169-75.
20. Ibrahim HR, Sugimoto Y, Aoki T. Ovotransferrin antimicrobial peptide (OTAP-92) kills bacteria through a membrane damage mechanism. Biochim Biophys Acta 2000; 1523: 196-205.
21. Giansanti F, Rossi P, Massucci MT, Botti D, Antonini G, Valenti P, et al. Antiviral activity of ovotransferrin discloses an evolutionary strategy for the defensive activities of lactoferrin. Biochem Cell Biol 2002; 80: 125-30.
22. Xie H, Huff GR, Huff WE, Balog JM, Rath NC. Effects of ovotransferrin on chicken macrophages and heterophil-granulocytes. Dev Comp Immunol 2002; 26: 805-15.
23. Otani H, Odashima M. Inhibition of proliferative responses of mouse spleen lymphocytes by lacto- and ovotransferrins. Food Agric Immunol 1997; 9: 193-202.
24. Hirota Y, Yang MP, Araki S, Yoshihara K, Furusawa S, Yasuda M, et al. Enhancing effects of chicken egg white derivatives on the phagocytic response in the dog. J Vet Med Sci 1995; 57: 825-9.
25. Babini GS, Livermore DM. Effect of conalbumin on the activity of Syn 2190, a 1,5 dihydroxy-4-pyridon monobactam inhibitor of AmpC beta-lactamases. J Antimicrob Chemother 2000; 45: 105-9.
26. Li-Chan ECY, Nakai S. Biochemical basis for the properties of egg white. Crit Rev Poult Biol 1989; 2: 21-58.
27. Mine Y. Recent advances in egg protein functionality in the food system. World Poul Sci J 2002; 58: 31-9.
28. Ibrahim HR. In: Yamamoto T, Juneja JR, Hatta H, Kim M Eds, Hen eggs, their basic and applied science. New York: CRC Press, Inc 1997; 37-56.
29. Vis EH, Plinck AF, Alink GM, van Boekel MAJS. Antimutagenicity of heat-denatured ovalbumin, before and after digestion, as compared to caseinate, BSA, and soy protein. J Agric Food Chem 1998; 46: 3713-8.
30. Fan X, Subramaniam R, Weiss MF, Monnier VM. Methylglyoxalbovine serum albumin stimulates tumor necrosis factor alpha secretion in RAW 264.7 cells through activation of mitogen-activating protein kinase, nuclear factor kappaB and intracellular reactive oxygen species formation. Arch Biochem Biophys 2003; 409: 274-86.
31. Vidovic D, Graddis T, Chen F, Slagle P, Diegel M, Stepan L, et al. Antitumor vaccination with HER-2-derived recombinant antigens. Int J Cancer 2002; 102: 660-4.
32. Goldberg J, Shrikant P, Mescher MF. In vivo augmentation of tumor-specific CTL responses by class I/peptide antigen complexes on microspheres (large multivalent immunogen). J Immunol 2003; 170: 228-35.
33. Nara E, Miyashita K, Ota T. Oxidative stability of PC containing linoleate and docosahexaenoate in an aqueous solution with or without chicken egg albumin. Biosci Biotech Biochem 1995; 59: 2319-20.
34. Hamachio Y, Hasegawa M. EPA powder as a functional ingredient. New Food Industry 1989; 31: 12-6.
35. Fujita H, Usui H, Kurahashi K, Yoshikawa M. Isolation and characterization of ovokinin, a bradykinin B1 agonist peptide derived from ovalbumin. Peptides 1995; 16: 785-90.
36. Matoba N, Usui H, Fujita H, Yoshikawa M. A novel anti-hypertensive peptide derived from ovalbumin induces nitric oxide-mediated vasorelaxation in an isolated SHR mesenteric artery. FEBS Lett 1999; 452: 181-4.
37. Yamada Y, Matoba N, Usui H, Onishi K, Yoshikawa M. Design of a highly potent anti-hypertensive peptide based on ovokinin(2-7). Biosci Biotechnol Biochem 2002; 66: 1213-7.
38. Yoshikawa M, Fujita H. In: Yano T, Matsuno R, Nakamura K, Eds, Developments in food engineering. New York: Blackie Academic and Professional 1994; 1053-5.
39. Tezuka H, Yoshikawa M. Annual Meeting of Japan Society for Bioscience, Biotechnology, and Agrochemistry Tokyo, 1995; 163.
40. Araki S, Suzuki M, Fujimoto M. Enhanced resistance to bacterial infections in mice by oral administration of an active egg white product. J Vet Med Sci 1992; 54: 1055-6.
41. Nakagawa J, Osame S, Ichijo S, Araki S, Kimura M. Effects of active egg white product on neutrophil function in calves. J Vet Med Sci 1993; 55: 259-63.
42. Yoshida T, Sakai M, Kitao T, Khlil SM, Araki S, Saitoh R, et al. Immunomodulatory effects of the fermented products of chicken egg, EF 203, on rainbow trout, Oncorhynchus mykiss. Aquaculture 1993;109: 207-14.
43. Kato I, Schrode J, Kohr WJ, Laskowski Jr M. Chicken ovomucoid: determination of its amino acid sequence, determination of the trypsin reactive site, and preparation of all three domains. Biochemistry 1987; 26: 193-201.
44. Cooke SK, Sampson HA. Allergenic properties of ovomucoid in man. J Immunol 1997; 159: 2026-32.
45. Kojima S, Takagi N, Minagawa T, Fushimi N, Miura KI. Effects of amino acid replacements around the reactive site of chicken ovomucoid domain 3 on the inhibitory activity toward chymotrypsin and trypsin. Protein Eng 1999; 12: 857-62.
46. Ibrahim HR. Insights into the structure-function relationships of ovalbumin, ovotransferrin, and lysozyme. In: Yamamoto T, Juneja, LR, Hatta H, Kim M Eds, Hen eggs. Boca Raton, Florida, 1996; 37-56.
47. Plate NA, Valuev IL, Sytov GA, Valuev LI. Mucoadhesive polymers with immobilized proteinase inhibitors for oral administration of protein drugs. Biomaterials 2002; 23: 1673-7.
48. Agarwal V, Nazzal S, Reddy IK, Khan MA. Transport studies of insulin across rat jejunum in the presence of chicken and duck ovomucoids. J Pharm Pharmacol 2001; 53: 1131-8.
49. Valueva TA, Mateev NL, Mosolov VV, Penin VA. Protein proteinase inhibitor therapy in experimental pancreatitis: pharmacological characterization of the inhibitor. Agents Actions Suppl 1992; 38(Pt 2): 203-10.
50. Holen E, Bolann B, Elsayed S. Novel B and T cell epitopes of chicken ovomucoid (Gal d 1) induce T cell secretion of IL-6, IL-13, and IFN-gamma. Clin Exp Allergy 2001; 31: 952-64.
51. Kijowski J, Lesnierowski G, Fabisz-Kijowska A. In: Sim JS, Nakai S, Guenter W Eds, Egg nutrition and biotechnology. Oxon, UK: CAB International 2000; 269-85.
52. Losso JN, Nakai S, Charter EA. Lysozyme. In: Naidu AS Ed, Natural food antimicrobial systems. New York: CRC Press, Inc 2000; 185-210.
53. Salton MJR. The properties of lysozyme and its action on microorganisms. Bacteriol Rev 1957; 21: 82-98.
54. Gill AO, Holley RA. Interactive inhibition of meat spoilage and pathogenic bacterial by lysozyme, nisin and EDTA in the presence of nitrite and sodium chloride at 24 degrees C. Int J Food Microbiol 2003; 80: 251-9.
55. Gill AO, Holley RA. Surface application of lysozyme, nisin, and EDTA to inhibit spoilage and pathogenic bacterial on ham and bologna. J Food Protect 2000; 63: 1338-436.
56. Nattress FM, Yost CK, Baker LP. Evaluation of the ability of lysozyme and nisin to control meat spoilage bacteria. Int J Food Microbiol 2001; 70: 111-9.
57. Ibrahim HR, Higashiguchi S, Juneja LR, Kim M, Yamamoto T. A structural phase of heat-denatured lysozyme with novel antimicrobial action. J Agric Food Chem 1996; 44: 1416-23.
58. Ibrahim HR. On the novel catalytically-indepenent antimicrobial function of hen egg-white lysozyme: a conformation-dependent activity. Nahrung 1998; 42: 187-93.
59. Masschalck B, Garcia-Graells C, Van Haver E, Michiels CW. Inactivation of high pressure resistant Escherichia coli by lysozyme and nisin under high pressure. Innov Food Sci Emerg Technol 2000; 1: 39-47.
60. Masschalck B, Van Houdt R, Van Haver EG, Michiels CW. Inactivation of gram-negative bacteria by lysozyme, denatured lysozyme, and lysozyme-derived peptides under high hydrostatic pressure. Appl Environ Microbiol 2001; 67: 339-44.
61. Ibrahim HR, Kobayashi K, Kato A. Length of hydrocarbon chain and antimicrobial action to gram-negative bacteria of fatty acylated lysozyme. J Agric Food Chem 1993; 41: 1164-8.
62. Ibrahim HR, Aoki T, Pellegrini A. Strategies for new antimicrobial proteins and peptides: lysozyme and aprotinin as model molecules. Curr Pharm Des 2002; 8: 671-93.
63. Pellegrini A, Thomas U, Bramaz N, Klauser S, Hunziker P, von Fellenberg R. Identification and isolation of a bactericidal domain in chicken egg white lysozyme. J Appl Microbiol 1997; 82: 372-8.
64. Ibrahim HR, Thomas U, Pellegrini A. A helix-loop peptide at the upper lip of the active site cleft of lysozyme confers potent antimicrobial activity with membrane permeabilization action. J Biol Chem 2001; 276: 43767-74.
65. During K, Porsch P, Mahn A, Brinkmann O, Gieffers W. The non-enzymatic microbicidal activity of lysozymes. FEBS Lett 1999; 449: 93-100.
66. Pellegrini A, Thomas U, Wild P, Schraner E, von Fellenberg R. Effect of lysozyme or modified lysozyme fragments on DNA and RNA synthesis and membrane permeability of Escherichia coli. Microbiol Res 2000; 155: 69-77.
67. Makki F, Durance TD. Thermal inactivation of lysozyme as influenced by pH, sucrose and sodium chloride and inactivation and preservative effect in beer. Food Res Int 1997; 29: 635-45.
68. Gerbaux V, Villa A, Monamy C, A Bertrand. Use of lysozyme to inhibit malolactic fermentation and to stabilize wine after malolactic fermentation. Am J Enol Viticult 1997; 48: 49-54.
69. Gao YC, Zhang G, Krentz S, Darius S, Power J, Lagarde G. Inhibition of spoilage lactic bacteria by lysozyme during wine alcoholic fermentation. Aust J Grape Wine Res 2002; 8: 76-83.
70. Nakamura S, Gohya Y, Losso JN, Nakai S, Kato A. Protective effect of of lysozyme-galactomannan or lysozyme-palmitic acid conjugates against Edwardsiella tarda infection in carp, Cyprinus carpio L. FEBS Lett 1996; 383: 251-4.
71. Sava G. Pharmacological aspects and therapeutic applications of lysozymes. EXS 1996; 75: 433-49.
72. Tenuovo J. Clinical applications of antimicrobial host proteins lactoperoxidase, lysozyme and lactoferrin in xerostomia: efficacy and safety. Oral Dis 2002; 8: 23-9.
73. Asakura K, Kojima T, Shirasaki H, Kataura A. Evaluation of the effects of antigen specific immunotherapy on chronic sinusitis in children with allergy. Auris Nasus Larynx 1990; 17: 33-8.
74. Sugahara T, Murakami F, Yamada Y, Sasaki T. The mode of actions of lysozyme as an immunoglobulin production stimulating factor. Biochim Biophys Acta 2000; 1475: 27-34.
75. Sava G. Reduction of B16 melanoma metastases by oral administration of egg-white lysozyme. Cancer Chemother Pharmacol 1989; 25: 221-2.
76. Sava G, Benetti A, Ceschia V, Pacor S. Lysozyme and cancer: role of exogenous lysozyme as anticancer agent (review). Anticancer Res 1989; 9: 583-91.
77. Sava G, Ceschia V, Pacor S, Zabucchi G. Observations on the antimetastatic action of lysozyme in mice bearing Lewis lung carcinoma. Anticancer Res 1991; 11: 1109-13.
78. Pacor S, Gagliardi R, Di Daniel E, Vadori M, Sava G. In vitro down regulation of ICAM-1 and E-cadherin and in vitro reduction of lung metastases of TS/A adenocarcinoma by a lysozyme derivative. Int J Mol Med 1999; 4: 369-75.
79. Green NM. Avidin. Adv Protein Chem 1975; 29: 85-133.
80. Bayer EA, Wilchek M. In: Sim JS, Nakai S, Eds, Egg uses and processing technologies, new developments. Oxon, UK: CAB International 1994; 158-76.
81. Wilchek M, Bayer EA. Avidin-biotin technology ten years on: has it lived up to its expectations? Trends Biochem Sci 1989; 14: 408-12.
82. Banks JG, Board RG, Sparks NHC. Natural antimicrobial systems and their potential in food preservation of the future. Biotech Appl Biochem 1986; 8: 103-47.
83. Korpela J, Salonen E-M, Kuusela P, Sarvas M, Vaheri A. Binding of avidin to bacteria and to the outer membrane porin of Escherichia coli. FEMS Microbiol Lett 1984; 22: 3-10.
84. Moro M, Pelagi M, Fulci G, Paganelli G, Dellabona P, Casorati G, et al. Tumor cell pretargeting with antibody-avidin complexes and biotinylated tumor necrosis factor alpha. Cancer Res 1977; 57: 192-8.
85. Corti A, Gasparri A, Sacchi A, Curnis F, Sangregorio R, Columbo B, et al. Tumor targeting with biotinylated tumor necrosis factor alpha: structure-activity relationships and mechanism of action on avidin pretargeted tumor cells. Cancer Res 1998; 58: 3866-72.
86. Gasparri A, Moro M, Curnis F, Sacchi A, Pagano S, Veglia F, et al. Tumor pretargeting with avidin improves the therapeutic index of biotinylated tumor necrosis factor alpha in mouse models. Cancer Res 1999; 59: 2917-23.
87. Yao Z, Zhang M, Sakahara H, Saga T, Arano Y, Konishi J. Avidin targeting of intraperitoneal tumor xenografts. J Natl Cancer Inst 1998; 90: 25-9.
88. Guttinger M, Guidi F, Chinol M, Reali E, Veglia F, Viale G, et al. Adoptive immunotherapy by avidin-driven cytotoxic T lymphocyte-tumor bridging. Cancer Res 2000; 60: 4211-15.
89. Bickel U, Yoshikawa T, Pardridge WM. Delivery of peptides and proteins through the blood-brain barrier. Adv Drug Deliv Rev 2001; 46: 247-79.
90. Rosebrough SF, Hartley DF. Biochemical modification of streptavidin and avidin: in vitro and in vivo analysis. J Nucl Med 1996; 37: 1380-4.
91. Chinol M, Casalini P, Maggiolo M, Canevari S, Omodeo ES, Caliceti P, et al. Biochemical modifications of avidin improve pharmacokinetics and biodistribution, and reduce immunogenicity. Br J Cancer 1998; 78: 189-97.
92. Caliceti P, Chinol M, Roldo M, Veronese FM, Semenzato A, Salmaso S, et al. Poly(ethylene glycol)-avidin bioconjugates: suitable candidates for tumor pretargeting. J Control Release 2002; 83: 97-108.
93. Barrett AJ. The cystatins: a diverse superfamily of cysteine peptidase inhibitors. Biomed Biochim Acta 1986; 45: 1363-74.
94. Nakai S. In: Sim JS, Nakai S, Guente WR Eds, Egg nutrition and biotechnology. Oxon, UK: CAB International, 2000; 205-17.
95. Ogawa M, Nakamura S, Scaman CH, Jing H, Kitts DD, Dou J, et al. Enhancement of proteinase inhibitory activity of recombinant human cystatin C using random-centroid optimization. Biochim Biophys Acta 2002; 1599: 115-24.
96. Nakamura S, Ogawa M, Nakai S. Effects of polymannosylation of recombinant cystatin C in yeast on its stability and activity. J Agric Food Chem 1998; 46: 2882-7.
97. 108T) on the freezing stability of recombinant chicken cystatin overexpressed in pichia pastoris X-33. J Agric Food Chem 2002; 50: 5313-7.
98. Bjorck L. Proteinase inhibition, immunoglobulin-binding proteins and a novel antimicrobial principle. Mol Microbiol 1990; 4: 1439-42.
99. Blankenvoorde MF, Henskens YM, van't Hof W, Veerman EC, Nieuw Amerongen AV. Inhibition of the growth and cysteine proteinase activity of Porphyromonas gingivalis by human salivary cystatin S and chicken cystatin. Biol Chem 1996; 377: 847-50.
100. Blankenvoorde MF, van't Hof W, Walgreen-Weterings E, van Steenbergen TJ, Brand HS, Veerman EC, et al. Cystatin and cystatin-derived peptides have antibacterial activity against the pathogen Porphyromonas gingivalis. Biol Chem 31998; 79: 1371-5.
101. Bjorck L, Grubb A, Kjellen L. Cystatin C, a human proteinase inhibitor, blocks replication of herpes simplex virus. J Virol 1990; 64: 941-3.
102. Ebina T, Tsukada K. Protease inhibitors prevent the development of human rotavirus-induced diarrhea in suckling mice. Microbiol Immunol 1991; 35: 583-8.
103. Kato T, Imatani T, Miura T, Minaguchi K, Saitoh E, Okuda K. Cytokine-inducing activity of family 2 cystatins. Biol Chem 2000; 381: 1143-7.
104. Verdot L, Lalmanach G, Vercruysse V, Hartmann S, Lucius R, Hoebeke R, et al. Cystatins up-regulate nitric oxide release from interferon-gamma-activated mouse peritoneal macrophages. J Biol Chem 1996; 271: 28077-81.
105. Verdot L, Lalmanach G, Vercruysse V, Hoebeke J, Gauthier F, Vray B. Chicken cystatin stimulates nitric oxide release from interferon-gamma-activated mouse peritoneal macrophages via cytokine synthesis. Eur J Biochem 1999; 266: 1111-7.
106. Das L, Datta N, Bandyopadhyay S, Das PK. Successful therapy of lethal murine visceral leishmaniasis with cystatin involves up-regulation of nitric oxide and a favourable T cell response. J Immunol 2001; 166: 4020-8.
107. Konduri SD, Yanamandra N, Siddique K, Joseph A, Dinh DH, Olivero WC, et al. Modulation of cystatin C expression impairs the invasive and tumorigenic potential of human glioblastoma cells. Oncogene 2002; 21: 8705-12.
108. Nagai A, Terashima M, Harada T, Shimode K, Takeuchi H, Murakawa Y, et al. Cathepsin B and H activities and cystatin C concentrations in cerebrospinal fluid from patients with leptomeningeal metastasis. Clin Chem Acta 2003; 329: 53-60.
109. Premzl A, Puizdar V, Zavasnik-Bergant V, Kopitar-Jerala N, Lah TT, Katunuma N, et al. Invasion of ras-transformed breast epithelial cells depends on the proteolytic activity of cysteine and aspartic proteinases. Biol Chem 2001; 382: 853-7.
110. Jiang S-T, Tzeng S-S, Wu W-T, Chen G-H. Enhanced expression of chicken cystatin as a thioredoxin fusion form in Escherichia coli AD494(DE3)pLysS and its effect on the prevention of surimi gel softening. J Agric Food Chem 2002; 50: 3731-7.
111. Carlander D, Kollberg H, Wejaker P-E, Larsson A. Peroral immunotherapy with yolk antibodies for the prevention and treatment of enteric infections. Immunol Res 2000; 21: 1-6.
112. Carlander D, Stalberg J, Larsson A. Chicken antibodies: a clinical chemistry perspective. Ups J Med Sci 1999; 104: 179-90.
113. Sim JS, Sunwoo HH, Lee EN. In: Naidu AS, Ed. Natural food antimicrobial systems. New York: CRC Press, 2000; 227-52.
114. Rose ME, Orlans E, Buttress N. Immunoglobulin classes in the hen's eggs: their segregation in yolk and white. Eur J Immunol 1974; 4: 521-3.
115. Schade R, Pfister C, Halatsch R, Henklein P. Polyclonal IgY antibodies from chicken egg yolk - an alternative to the production of mammalian IgG type antibodies in rabbits. ATLA 1991; 19: 403-19.
116. Gassmann M, Thommes P, Weiser T, Hubscher U. Efficient production of chicken egg yolk antibodies against a conserved mammalian protein. FASEB J 1990; 4: 2528-32.
117. Yolken RH, Leister F, Wee SB, Miskuff R, Vonderfecht S. Antibodies to rotavirus in chickens' eggs: a potential source of antiviral immunoglobulins suitable for human consumption. Pediatrics 1988; 81: 291-5.
118. Kuroki M, Ohta Y, Ikemori Y, Peralta RC, Yokoyama H, Kodama Y. Passive protection against bovine rotavirus in calves by specific immunoglobulins from chicken egg yolk. Arch Virol 1994; 138: 143-8.
119. Hatta H, Tsuda K, Akachi S, Kim M, Yamamoto T, Ebina T. Oral passive immunization effect of anti-human rotavirus IgY and its behavior against proteolytic enzymes. Biosci Biotech Biochem 1993; 57: 1077-81.
120. Ebina T. Prophylaxis of rotavirus gastroenteritis using immunoglobulin. Arch Virol Suppl 1996; 12: 217-23.
121. Kovacs-Nolan J, Sasaki E, Yoo D, Mine Y. Cloning and expression of human rotavirus spike protein, VP8*, in Escherichia coli. Biochem Biophys Res Commun 2001; 282: 1183-8.
122. Ikemori Y, Ohta M, Umeda K Jr, Icatlo FC, Kuroki M, Yokoyama H, et al. Passive protection of neonatal calves against bovine coronavirus-induced diarrhea by administration of egg yolk or colostrum antibody powder. Vet Microbiol 1997; 58: 105-11.
123. Ikemori Y, Kuroki M, Peralta RC, Yokoyama H, Kodama Y. Protection of neonatal calves against fatal enteric colibacillosis by administration of egg yolk powder from hens immunized with K99-piliated enterotoxigenic Escherichia coli. Am Vet Res 1992; 53: 2005-8.
124. O'Farrelly C, Branton D, Wanke CA. Oral ingestion of egg yolk immunoglobulin from hens immunized with an enterotoxigenic Escherichia coli strain prevents diarrhea in rabbits challenged with the same strain. Infect Immun 1992; 60: 2593-7.
125. Yokoyama H, Peralta RC, Diaz R, Sendo S, Ikemori Y, Kodama Y. Passive protective effect of chicken egg yolk immunoglobulins against experimental enterotoxigenic Escherichia coli infection in neonatal piglets. Infect Immun 1992; 60: 998-1007.
126. Imberechts H, Deprez P, Van Driessche E, Pohl P. Chicken egg yolk antibodies against F18ab fimbriae of Escherichia coli inhibit shedding of F18 positive E. coli by experimentally infected pigs. Vet Microbiol 1997; 54: 329-41.
127. Jin LZ, Samuel K, Baidoo K, Marquardt RR, Frohlich AA. In vitro inhibition of adhesion of enterotoxigenic Escherichia coli K88 to piglet intestinal mucus by egg yolk antibodies. FEMS Immunol. Med Microbiol 1998; 21: 313-21.
128. Marquardt RR, Jin LZ, Kim JW, Fang L, Frohlich AA, Baidoo SK. Passive protective effect of egg yolk antibodies against enterotoxigenic Escherichia coli K88+ infection in neonatal and early weaned piglets. FEMS Immunol Med Microbiol 1999; 23: 283-8.
129. Amaral JA, Tino De Franco M, Carneiro-Sampaio MM, Carbonare SB. Anti-enteropathogenic Escherichia coli immunoglobulin Y isolated from eggs laid by immunized Leghorn chickens. Res Vet Sci 2002; 72: 229-34.
130. Peralta RC, Yokoyama H, Ikemori Y, Kuroki M, Kodama Y. Passive immunization against experimental salmonellosis in mice by orally administered hen egg yolk antibodies specific for 14-kDa fimbriae of Salmonella enteritidis. J Med Microbiol 1994; 41: 29-35.
131. Yokoyama H, Peralta RC, Umeda K, Hashi T, Icatlo FC, Kuroki M, et al. Prevention of fatal salmonellosis in neonatal calves, using orally administered chicken egg yolk Salmonella-specific antibodies. Am J Vet Res 1998; 59: 416-20.
132. Yokoyama H, Umeda K, Peralta RC, Hashi T, Icatlo F, Kuroki M, et al. Oral passive immunization against experimental salmonellosis in mice using chicken egg yolk antibodies specific for Salmonella enteritidis and S. typhimurium. Vaccine 1998; 16: 388-93.
133. Sugita-Konishi Y, Ogawa M, Arai S, Kumagai K, Igimi S, Shimizu M. Blockade of Salmonella enteritidis passage across the basolateral barriers of human intestinal epithelial cells by specific antibody. Microbiol Immunol 2000; 44: 473-9.
134. Lee EN, Sunwoo HH, Menninen K, Sim JS. In vitro studies of chicken egg yolk antibody (IgY) against Salmonella enteritidis and Salmonella typhimurium. Poult Sci 2002; 81: 632-41.
135. Lee SB, Mine Y, Stevenson RMW. Effects of hen egg yolk immunoglobulin in passive protection of rainbow trout against Yersinia ruckeri. J Agric Food Chem 2000; 48: 110-5.
136. Hatta H, Mabe K, Kim M, Yamamoto T, Gutierrez MA, Miyazaki T. In: JS Sim JS, S Nakai S, Eds, Egg uses and processing technologies, new developments. Oxon, UK: CAB International 1994; 241-9.
137. Shin JH, Yang M, Nam SW, Kim JT, Myung NH, Bang WG, et al. Use of egg yolk-derived immunoglobulin as an alternative to antibiotic treatment for control of Helicobacter pylori infection. Clin Diagn Lab Immunol 2002; 9: 1061-6.
138. Kweon C-H, Kwon B-J, Woo S-R, Kim J-M, Woo G-H, Son D-H, et al. Immunoprophylactic effect of chicken egg yolk immunoglobulin (IgY) against porcine epidemic diarrhea virus (PEDV) in piglets. J Vet Med Sci 2000; 62: 961-4.
139. Eterradossi N, Toquin D, Abbassi H, Rivallan G, Cotte JP, Guittet M. Passive protection of specific pathogen free chicks against infectious bursal disease by in-ovo injection of semi-purified egg-yolk antiviral immunoglobulins. J Vet Med 1997; B44: 371-83.
140. Sugita-Konishi Y, Shibata K, Yun SS, Yukiko HK, Yamaguchi K, Kumaga S. Immune functions of immunoglobulin Y isolated from egg yolk of hens immunized with various infectious bacteria. Biosci Biotech Biochem 1996; 60: 886-8.
141. LeClaire RD, Hunt RE, Bavari S. Protection against bacterial superantigen staphylococcal enterotoxin B by passive immunization. Infect Immun 2002; 70: 2278-81.
142. Otake S, Nishihara Y, Makimura M, Hatta H, Kim M, Yamamoto T, et al. Protection of rats against dental caries by passive immunization with hen egg yolk antibody (IgY). J Dent Res 1991; 70: 162-6.
143. Hatta H, Tsuda K, Ozeki M, Kim M, Yamamoto T, Otake S, et al. Passive immunization against dental plaque formation in humans: Effect of a mouth rinse containing egg yolk antibodies (IgY) specific to Streptococcus mutans. Caries Res 1997; 31: 268-74.
144. Chang HM, Ou-Yang RF, Chen YT, Chen CC. Productivity and some properties of immunoglobulin specific against Streptococcus mutans serotype c in chicken egg yolk (IgY). J Agric Food Chem 1999; 47: 61-6.
145. Smith DJ, King WF, Godiska R. Passive transfer of immunoglobulin Y to Streptococcus mutans glucan binding protein B can confer protection against experimental dental caries. Infect Immun 2001; 69: 3135-42.
146. Thalley BS, Carroll SB. Rattlesnakes and scorpion antivenoms from the egg yolk of immunized hens. Biotechnology 1990; 8: 934-7.
147. Almeida CM, Kanashiro MM, Rangel Filho FB, Mata MF, Kipnis TL. Development of snake antivenom antibodies in chickens and the purification from yolk. Vet Rec 1998; 143: 579-84.
148. Larsson A, Balow R, Lindahl TL, Forsberg P. Chicken antibodies: taking advantage of evolution; a review. Poult Sci 1993; 72: 1807-12.
149. Worledge KL, Godiska R, Barrett TA, Kink JA. Oral administration of avian tumor necrosis factor antibodies effectively treats experimental colitis in rats. Dig Dis Sci 2000; 45: 2298-305.
150. Yang J, Jin Z, Yu Q, Yang T, Wang H, Liu L. The selective recognition of IgY for digestive system cancers. Chin J Biotechnol 1997; 13: 85-90.
151. Taborsky G, Mok C. Phosvitin: homogeneity of molecular weight. J Biol Chem 1967; 242: 1495-501.
152. Byrne BM, van het Schip AD, van de Klundert JAM, Arnberg AC, Gruber M, Ab G. Amino acid sequence of phosvitin derived from the nucleotide sequence of part of the chicken vitellogenin gene. Biochemistry 1984; 23:4275-79.
153. Greengard O, Sentenac A, Mendelsohn N. Phosvitin, the iron carrier of egg yolk. Biochim Biophys Acta 1964; 90: 406-7.
154. Morris ER, Greene FE. Utilization of the iron of egg yolk for hemoglobin formation by the growing rat. J Nutr 1972; 102: 901-8.
155. Sato R, Lee YS, Noguchi T, Naito H. Iron solubility in the small intestine of rats fed egg yolk protein. Nut Report Int 1984; 30: 1329-36.
156. Sato R, Noguchi T, Naito H. The formation and Iron binding property of phosphopeptides in the small intestinal contents of rats fed egg yolk diet. Nut Report Int 1985; 31: 245-52.
157. Sato R, Noguchi T, Naito H, The effect of feeding demineralized egg yolk protein on the solubility of intra-intestinal iron. Nut Report Int 1987; 36: 593-602.
158. Jiang B, Mine Y. Preparation of novel functional oligophosphopeptides from hen egg yolk phosvitin. J Agric Food Chem 2000; 48: 990-4.
159. B Jiang B, Y Mine Y. Phosphopeptides derived from hen egg yolk phosvitin: effect of molecular size on the calcium-binding properties. Biosci Biotechnol Biochem 2001; 65: 1187-90.
160. Lu CL, Baker R. Characteristics of egg yolk phosvitin as an antioxidant for inhibiting metal-catalyzed phospholipid oxidations. Poultry Sci 1986; 65: 2065-70.
161. Cook WH, Martin WG. In: Tria E, Scanu AM, Eds, Structure and functional aspects of lipoproteins in living systems. New York: Academic Press 1962; 579-615.
162. Martin WG, Tattrie NH, Cook WH. Lipid extraction and distribution studies of egg yolklipoproteins. Can J Biochem Physiol 1963; 41: 657-66.
163. Suzuki M, Shinohara H, Yonekura M, Tsutsumi M, Shinohara K. Growth promoting effect of chicken egg yolk lipoproteins on human lymphocytic cell lines. Nippon Shokuhin Kogyo Gakkaishi 1994; 41: 37-42.
164. Shinohara K, Kakiuchi T, Kobori M, Suzuki M, Fukushima T. Europium-liked immunoassay of IgM production by human-human hybridomas cultured with or without chicken egg yolk lipoprotein. Biosci. Biotech. Biochem 1993; 57: 1012-3.
165. Moussa M, Marinet V, Trimeche A, Tainturier D, Anton M. Low density lipoprotein extracted from hen egg yolk by an easy method: cryoprotective effect on frozen-thawed bull semen. Theriogenology 2002; 57: 1695-706.
166. Pouliot Y, Gauthier SF, Groleau, PE. In: Mine Y Shahidi F Eds, Nutraceutical proteins and peptides in health and diseases. Boca Raton, FL, CRC Taylor & Francis, 2006; 639-655.
167. Lanzavecchia G. Phylogeny and genetic code: evolution and conservation. Curr Pharm Des 2006; 12(24): 2997-3013.
168. Rychly J, Nebe B. Therapeutic strategies in autoimmune diseases by interfering with leukocyte endothelium interaction. Curr Pharm Des 2006; 12(29): 3799-806.
169. Villar CC, Dongari-Bagtzoglou A. Therapeutic modulation of cytokines in chronic infectious diseases. Curr Pharm Des 2006; 12(19): 2329-48.